

**510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION
DECISION SUMMARY**

A. 510(k) Number:

K073381

B. Purpose for Submission:

New application

C. Measurand:

EBV viral capsid antigen (VCA) and heterophile antibodies

D. Type of Test:

Multiplexed Flow Immunoassay

E. Applicant:

Focus Diagnostics, Inc.

F. Proprietary and Established Names:

Plexus™ EBV IgM Multi-Analyte Diagnostics Test Kit

G. Regulatory Information:

1. Regulation section: 21 CFR 866.3235, Epstein-Barr virus serological reagents
2. Product code: LJN
3. Classification: Class: I
4. Panel: 83 Microbiology

H. Intended Use:

Focus Diagnostics' Plexus™ EBV IgM Multi-Analyte Diagnostics test kit is intended for qualitatively detecting the presence or absence of human IgM class antibodies to viral capsid antigen (VCA), and heterophile antibodies in human sera. The test is indicated as an aid in the diagnosis of EBV infection and EBV-associated infectious mononucleosis.

The performance of this assay has not been established for use in the diagnosis of nasopharyngeal carcinoma and Burkitt's lymphoma, for testing of immunocompromised

patients, for use by a point of care facility or for use with automated equipment. This assay has not been evaluated for donor screening.

2. Indication(s) for use:

Same as Intended Use

3. Special conditions for use statement(s):

For prescription use only

4. Special instrument requirements:

Instrument: The Luminex xMAP® System.

Software: Plexus™ Multi Analyte Diagnostic Software for Luminex xMAP instrument with Luminex IS 2.3 software (SW.MP0001)

I. Device Description:

The Focus Diagnostics Plexus™ EBV IgM uses an Antigen Bead suspension that contains two distinct EBV antigen bead types (VCA and Heterophile) and one process control bead type that fluoresce at different wavelengths and/or intensities.

1. Patient sera are diluted, and the diluted sera are incubated with Antigen Beads. If EBV antibodies are present, then the antibodies bind to the corresponding antigen beads.
2. Phycoerythrin-conjugated goat Anti-human IgM (Conjugate) is added, binds to the bound EBV antibody (if present), and forms a Conjugate-EBV antibody-antigen bead sandwich.
3. Fluorescence from each distinct EBV antigen bead type is measured and compared against a Cutoff Calibrator.

J. Substantial Equivalence Information:

1. Predicate device name(s):

Athena Multi-Lyte EBV VCA IgM Test System
Osom® Mono Test

2. Predicate 510(k) number(s):

K042092 - Athena Multi-Lyte EBV VCA IgM Test System
K972231 - Osom® Mono Test

3. Comparison with predicate:

Predicate Device 1: Athena Multi-Lyte EBV VCA IgM Test System

Similarities		
Item	Device	Predicate
Intended use	Qualitative detection of EBV VCA IgM antibodies to aid in diagnosis of infectious mononucleosis	Qualitative detection of EBV VCA IgM antibodies to aid in diagnosis of infectious mononucleosis
Specimen type	Serum	Serum
Method	Qualitative	Qualitative
Antigen	EBV VCA gp 125	EBV VCA gp125
Differences		
Item	Device	Predicate
Type of assay	Multiplex Microbead Immunoassay (MMIA) based on Luminex XMAP technology.	Multiplex Flow cytometry immunoassay
Interpretation of test results	Automated calculations using Plexus software.	AtheNA Multi-Lyte instrument software

Predicate Device 2: Osom® Mono Test, Heterophile

Similarities		
Item	Device	Predicate
Intended use	Qualitative detection of EBV heterophile IgM antibodies to aid in diagnosis of infectious mononucleosis	Qualitative detection of EBV heterophile IgM antibodies to aid in diagnosis of infectious mononucleosis
Differences		
Item	Device	Predicate
Method	Qualitative	Quantitative
Specimen type	Serum	Serum, plasma, blood
Type of assay	Multiplex Microbead	Immunochromatorgraphy

Antigen	Immunoassay (MMIA) based on Luminex XMAP technology. Heterophile: purified protein	Heterophile: native protein
Interpretation of test results	Automated calculations	Visual evaluation

K. Standard/Guidance Document Referenced (if applicable):

Guidance for Industry and FDA Staff, Format for Traditional and Abbreviated 510(k), 08/12/2005, (<http://www.fda.gov/cdrh/ode/guidance/1567.pdf>)

Off-The-Shelf Software Use in Medical Devices, 09/9/1999, (<http://www.fda.gov/cdrh/ode/guidance/585.pdf>)

Cyber security for Networked Medical Devices Containing Off-The-Shelf (OTS) Software, 01/14/2005, (<http://www.fda.gov/cdrh/comp/guidance/1553.pdf>)

Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices, 05/11/2005, (<http://www.fda.gov/cdrh/ode/guidance/337.pdf>)

General Principles of Software Validation, 01/11/2002, (<http://www.fda.gov/cdrh/comp/guidance/938.pdf>)

L. Test Principle:

Multiplexed flow immunoassay

M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

The inter/intra-assay reproducibility and the inter-laboratory reproducibility testing were performed at three laboratories. Each of the three laboratories tested twelve samples in triplicate on five different days. For positive specimens, the inter-lab % CV varied from 9-16% for VCA IgM and 7 -14% for heterophile antibody assays.

b. Linearity/assay reportable range:

Not applicable

c. *Traceability, Stability, Expected values (controls, calibrators, or methods):*

Not applicable

d. *Detection limit:*

Not applicable

e. *Analytical specificity:*

A cross-reactivity study was performed to determine if samples from various disease states and other potentially cross-reactivity factors interfere with test results when tested with the Plexus EBV IgM kit.

Cross-Reactivity								
Cross Reactives	N	Method	EBV VCA IgM			EBV Heterophile		
			Positive	Equivocal	Negative	Positive	Equivocal	Negative
ANA	28	Plexus	0	2	26	0	0	28
		ELISA	0	0	28	0	0	28
		Discrepant	2 ²			0		
Cytomegalovirus (CMV)	25	Plexus ⁴	2	1	21	0	0	24
		ELISA	1	0	24	0	0	25
		Discrepant	5 ¹			1 ⁴		
HSV 1 & HSV 2	2	Plexus	0	0	2	0	0	2
		ELISA	0	0	2	0	0	2
		Discrepant	0			0		
Rheumatoid Factor (Rh)	29	Plexus	4	0	25	0	0	29
		ELISA	0	0	29	0	0	29
		Discrepant	4			0		
Rubella	5	Plexus	0	0	5	0	0	5
		ELISA	0	0	5	0	0	5
		Discrepant	0			0		
Varicella-zoster (VZV)	42	Plexus	2	1	39	2	0	40
		ELISA	1	2	39	2	0	40
		Discrepant	3 ³			0		

¹One Equivocal Sample; ²Two Equivocal Samples; ³Three Equivocal Samples; ⁴One Invalid Sample

f. *Assay cut-off:*

Establishment of the cutoff values for the EBV IgM Plexus was performed using 585 patient serum samples submitted for EBV testing. These samples were first tested on the predicate devices (Diamedix ELISA for VCA IgM, and the Accutest for infectious mononucleosis). Each sample was classified as positive, negative or equivocal for each of these assays. The serum samples were then run on the EBV IgM Plexus assay. Comparisons were made for each analyte with its respective predicate test (excluding equivocal samples on the predicated device) on a Reciever Operating Characteristics (ROC) analysis. Based on the ROC analysis graphs a cutoff value was obtained.

Plexus™ EBV IgM Multi-Analyte Diagnostics					
Antigen	Positive With predicate Device	% Positive Agreement (sensitivity)	Negative With predicate Device	% Negative Agreement (specificity)	Cutoff score
Heterophile	62	91.9% 57/62	522	90.4% 472/522	0.664
VCA IgM	123	83.7% 103/123	447	93.1% 416/447	0.849

2. Comparison studies:

a. *Method comparison with predicate device:*

Method Comparison: EBV VCA IgM Assay

Performance of the Plexus EBV VCA IgM analyte was tested against a combination (hereafter referred to as ‘consensus comparator’) of a FDA-cleared commercially available ELISA, an immunofluorescent (IFA) test and a flow cytometry based immunoassay. For each sample, a consensus based algorithm (2/3) was used to determine the predicate result for comparison with the Plexus VCA IgM result. Serological status was determined by the use of commercially available ELISA assays for the EBV analytes EBNA-1 IgG, VCA IgG, EA-D IgG, VCA IgM and heterophile antibody.

EBV VCA-IgM vs. Consensus Comparator: Comparison by serological status of prospective population (N = 723). Samples were collected and tested by a Northeast investigator (n = 350), a Mid-West investigator (n=249), and Focus (n=124).

EBV VCA IgM Results							
		Consensus Predicate		Plexus			
Serological Status by Predicates			n	Positive	Equivocal	Negative	% Agreement
Acute	Primary Acute	Positive	59	56	2	1	94.9%(56/59), 95% CI:86.1-98.3%
		Negative	1	0	0	1	100%(1/1), 95% CI:20.7-100%
		No consensus	0	0	0	0	NA
	Late Acute	Positive	14	9	1	4	64.3%(9/14), 95% CI:38.8-83.7%
		Negative	58	2	0	56	96.6%(56/58), 95% CI:88.3-99%
		No consensus	0	0	0	0	NA
Recovering	Positive	0	0	0	0	NA	
	Negative	1	0	0	1	100%(1/1), 95% CI:20.7-100%	
	No consensus	0	0	0	0	NA	
Previous Infection	Positive	1	0	0	1	0%(0/1), 95% CI:0-79.3%	
	Negative	296	9	1	286	96.3%(286/297), 95% CI:93.5-97.9%	
	No consensus	1	1	0	0	NA	
No Infection	Positive	1	1	0	0	50%(1/2), 95% CI:9.5-90.5%	
	Negative	225	0	0	225	100%(225/225), 95% CI:98.3-100%	
	No consensus	1	0	0	1	NA	
Indeterminate ¹	Positive	13	13	0	0	81.3%(13/16), 95% CI:57.0-93.4%	
	Negative	49	1	0	48	98%(48/49), 95% CI:89.3-99.6%	
	No consensus	3	0	0	3	NA	

¹ No consensus results: the combination of three predicates could not yield a conclusive result for these samples – a 2/3 majority could not be obtained.

EBV VCA IgM vs. Consensus Comparator: Comparison by serological status of retrospective presumed acute population. Samples were collected and tested by a Mid-West investigator ($n=150$).

EBV VCA IgM Results							
		Consensus Predicate		Plexus			
Serological Status by Predicates			n	Positive	Equivocal	Negative	% Agreement
Acute	Primary Acute	Positive	104	103	0	1	99%(103/104), 95% CI:94.8-99.8%
		Negative	1	0	0	1	50%(1/2), 95% CI:9.5-90.5%
		No consensus	1	1	0	0	NA
	Late Acute	Positive	8	7	0	1	87.5%(7/8), 95% CI:52.9-97.8%
		Negative	0	0	0	0	NA

EBV VCA IgM Results							
		Consensus Predicate		Plexus			
Serological Status by Predicates			n	Positive	Equivocal	Negative	% Agreement
		No consensus	0	0	0	0	NA
No Infection		Positive	0	0	0	0	NA
		Negative	2	1	0	1	50%(1/2), 95% CI:9.5-90.5%
		No consensus	0	0	0	0	NA
Indeterminate ¹		Positive	31	30	0	1	93.8%(30/32), 95% CI:79.9-98.3%
		Negative	2	2	0	0	0%(0/2), 95% CI:0-65.8%
		No consensus	1	0	0	1	NA

¹ No consensus results: the combination of three predicates could not yield a conclusive result for these samples – a 2/3 majority could not be obtained.

Method Comparison: EBV Heterophile Assay

EBV Heterophile vs. Predicate: Comparison by serological status of prospective population (N = 723). Samples were collected and tested by a Northeast investigator (n = 350), a Mid-West investigator (n=249), and Focus (n=124).

EBV Heterophile IgM Results							
		Predicate Heterophile Rapid Test		Plexus			
Serological Status by Predicates			n	Positive	Equivocal	Negative	% Agreement
Acute	Primary Acute	Positive	51	48	0	3	94.1%(48/51), 95% CI:84.1-98%
		Negative	9	1	0	8	88.9%(8/9), 95% CI:56.5-98%
	Late Acute	Positive	5	2	0	3	40%(2/5), 95% CI:11.8-76.9%
		Negative	67	1	0	66	98.5%(66/67), 95% CI:92-99.7%
Recovering		Positive	0	0	0	0	NA
		Negative	1	0	0	1	100%(1/1), 95% CI:20.7-100%
Previous Infection		Positive	0	0	0	0	NA
		Negative	298	2	0	296	99.3%(296/298), 95% CI:97.6-99.8%
No Infection		Positive	0	0	0	0	NA
		Negative	227	3	0	224	98.7%(224/227), 95% CI:96.2-99.5%
Indeterminate		Positive	19	10	0	9	52.6%(10/19), 95% CI:31.7-72.7%
		Negative	46	0	0	46	100%(46/46), 95% CI:92.3-100%

EBV Heterophile vs Predicate: Comparison by serological status of retrospective presumed acute population. Samples were collected and tested by a Mid-West investigator ($n=150$).

EBV Heterophile IgM Results							
		Predicate Heterophile Rapid Test	Plexus				
Serological Status by Predicates			n	Positive	Equivocal	Negative	% Agreement
Acute	Primary Acute	Positive	87	75	2	10	86.2%(75/87), 95% CI:77.4-91.9%
		Negative	19	2	0	17	89.5%(17/19), 95% CI:68.6-97.1%
	Late Acute	Positive	3	2	0	1	66.7%(2/3), 95% CI:20.8-93.9%
		Negative	5	0	0	5	100%(5/5), 95% CI:56.6-100%
No Infection		Positive	0	0	0	0	NA
		Negative	2	0	0	2	100%(2/2), 95% CI:34.2-100%
Indeterminate		Positive	22	21	1	0	95.5%(21/22), 95% CI:78.2-99.2%
		Negative	12	1	0	11	91.7%(11/12), 95% CI:64.6-98.5%

b. *Matrix comparison:*

Not applicable

3. Clinical studies:

a. *Clinical Sensitivity:*

Not applicable

b. *Clinical specificity:*

Not applicable

c. Other clinical supportive data (when a. and b. are not applicable):

Not applicable

4. Clinical cut-off:

See 1 f

5. Expected values/Reference range:

Not applicable

N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.